Work

Abstract 841: The preclinical pharmacokinetics and pharmacodynamics of AZD0022: A potent, oral KRASG12D-selective agent exhibiting oral bioavailability and KRAS pathway suppression in the GP2D xenograft model

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-841

Authors: Kevin Beaumont, Sofia Guzzetti, Pablo Morentin-Gutierrez, Rhys D. Jones, Ken Grime, Carla Martins, Alex Koers, Alison Peter, Simon T. Barry, Susan Critchlow, Michele Moschetta, Michael Niedbala

Institutions: AstraZeneca (United Kingdom), AstraZeneca (United States)

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409625760

Cites:

Cited by: 4

Related to: 10